Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02895100 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Protagonist Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT02895100: Clinical Trial Phase 2 study, sponsored by Protagonist Therapeutics.
NCT02895100 is a Phase 2 study that was terminated before completion, run by Protagonist Therapeutics. The registered enrollment target is 98 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02895100, a Phase 2 study, was terminated before completion, sponsored by Protagonist Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
The main objectives of this study are to evaluate the efficacy, safety, and tolerability of daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
Primary Outcome
The primary efficacy endpoint for this study was the proportion of subjects receiving PTG-100 with clinical remission at Week 12. Clinical remission was defined using the Mayo subscores of stool frequency, rectal bleeding, and endoscopy.
Interventions
- DRUG Placebo
- DRUG PTG-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-03-26 |
| Phase | Phase 2 |
Why NCT02895100 stopped before completion
NCT02895100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02895100 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02895100 about?
NCT02895100 is a clinical study titled "Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis". The main objectives of this study are to evaluate the efficacy, safety, and tolerability of daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
What is the current status of trial NCT02895100?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2016-12. Estimated completion is 2018-03-26.
What interventions are being tested in trial NCT02895100?
The interventions under investigation include: Placebo (DRUG), PTG-100 (DRUG).
Who is sponsoring clinical trial NCT02895100?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02895100's enrollment target sits among peer trials
98 743rd of 2000 higher than 1,255 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia